Le-Meredian Madinah Al Madinah - Saudi Arabia 26-27 Jan,...

An Initiative of

Le-Meredian MadinahAl Madinah - Saudi Arabia

26-27 Jan, 2018

S a u d i C a n c e r F o u n d a t i o n

CME15 accredited

Al Madinah - Saudi Arabia 26-27 Jan, 2018

1

Index

Welcome Letter ................................................................................................ 02

History of SABCSTM ........................................................................................ 06

SABCSTM Committee ..................................................................................... 11

Best of SABCSTM Local Committee .............................................................. 12

Program Agenda .............................................................................................. 18

Abstracts ........................................................................................................... 00

Notes ................................................................................................................ 36

2

Welcome

Dear Colleagues,

The Organizing Committee of the San Antonio Breast Cancer SymposiumTM (SABCSTM) , the Saudi Cancer Foundation and Saudi Ministry of Health welcome you to the Best of SABCSTM Saudi Arabia.

The SABCSTM, now in its 40th year, is the premier conference for basic, translational, and clinical cancer research professionals. It is well known for presenting the latest breast cancer data from all over the world.

The Best of SABCSTM allows professionals, who are unable to travel to San Antonio, the opportunity to experience and discuss the research and advances with colleagues and key opinion leaders.

Attendees to the Best of SABCSTM program will receive the most current information on breast cancer research presented in the original format delivered at the meeting in San Antonio in December 2016. You will learn of the current advances in breast cancer research that are changing clinical practice for the benefit of patients.

Principal subject areas of the Best of SABCSTM Saudi Arabia program include:

• Cancer Immunology 101;

• Triple Negative Breast Cancer;

• Breast Cancer Prevention: Consolidating Gains and Charting New Directions

• Follow-up Care and Lifestyle Recommendations to Improve Outcomes

• HER2+ Breast Cancer and,

• Assessment and Treatment of Older Adults with Breast Cancer


3

The SABCSTM has always been a forum for interaction between individuals involved with all aspects of breast cancer research and care and it is envisioned that this camaraderie will also be experienced at the Best of SABCSTM Saudi Arabia.

I would like to extend recognition and thanks to the supporter(s) of the Best of SABCSTM, Encore Medical Education, for realizing the importance of education and who make it possible to bring this meeting to Saudi Arabia.

On behalf of the organizing committee of the SABCSTM, the Saudi Cancer Foundation and Saudi Ministry of Health

I would like to wish you fruitful conference.

Sincerely,

Virginia G. Kaklamani, MDProfessor of Medicine, Division of Hematology/Oncology, UT Health Science Center San Antonio, San Antonio, Texas,USA

Dr. Omalkhair AbulkhairChairman, Organizing Committee


5

6

SABCS™ History

The First Annual San Antonio Breast Cancer SymposiumTM was held November 11, 1978 during Breast Cancer Awareness Week, and was part of an intensive 3-year outreach program of public and professional education designed to significantly reduce the death rate caused by breast cancer in San Antonio and surrounding counties. It was sponsored by Cancer Therapy and Research Center (CTRC) and the American Cancer Society, Texas Division, in conjunction with The University of Texas Health Science Center at San Antonio (UTHSCSA) and the Bexar County Medical Society. That all-day course for physicians and surgeons was organized and co-directed by Charles A. Coltman, Jr., MD and William L. McGuire, MD, both Professors of Medicine at UTHSCSA. It featured invited presentations by a panel of internationally known specialists and was attended by 141 physicians and surgeons from a 5-state area. Three years later, in 1981, the meeting was expanded to two days, a call for abstracts was distributed worldwide, and proffered papers for slide and poster presentations were incorporated into the program, thereby broadening its scope to both attract and draw from a larger, international base. Renowned experts gave formal plenary lectures, and accepted abstracts were published for the first time in the peer-reviewed journal Breast Cancer Research and Treatment. Case discussion lunches offered opportunity for discussion of complex clinical problems in the management of primary and metastatic disease, by a panel of physicians from different disciplines.

Although some modifications have been made in the format, such as incorporating pre-symposium educational sessions, Year In Review and lunchtime forums the overall format remains very much the same. This reflects the objective of the Symposium, which is to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.

In 1990, CTRC and UTHSCSA formally entered into a collaboration known as the San Antonio Cancer Institute (an NCI designated Comprehensive Cancer Center), which in 1995 assumed direct sponsorship of the Symposium. In 1992, C. Kent Osborne, MD became Co-Director of the symposium upon the death


7

of William L. McGuire, MD. In 1999, Dr. Osborne left UTHSCSA and opened the Breast Center at Baylor College of Medicine, and in 2005, Baylor College of Medicine became a joint sponsor of the symposium. In 2008 the American Association for Cancer Research became a joint sponsor of the symposium. Through the efforts of UTHSCSA, AACR, and BCM, the program attracts more thought-leaders and high-quality proffered papers in basic and translational breast cancer research as well as increasing the participation of young investigators by providing superior education and training opportunities for the next generation of breast cancer researchers.

The driving force behind the collaboration is the shared mission of the partners to advance progress against breast cancer. By combining their respective strengths, the partnership will produce a scientific meeting that encompasses the full spectrum of breast cancer research, facilitating the rapid translation of new knowledge into better care for breast cancer patients.

In 2010 Peter M. Ravdin, MD, PhD, Ruth McLean Bowman Bowers Chair for Breast Cancer Research & Treatment, Director of the Breast Cancer Program at the Cancer Therapy & Research Center at UT Health Science Center assumed the role of Co-Director of the symposium upon the retirement of Charles A. Coltman, Jr, MD. Dr. Coltman remains Co-Director, ex-officio.

In 2011 Carlos L. Arteaga, Professor of Medicine and Cancer Biology, Interim Director, Division of Hematology-Oncology, Director, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University was appointed Co-Director of the symposium representing American Association for Cancer Research.

In 2014 Ismail Jatoi, MD, Professor and Division Chief Surgical Oncology at UT Health Science Center assumed the role of acting Co-Director of the symposium upon the retirement of Peter M. Ravdin, MD, PhD.

In 2015 Virginia G. Kaklamani, Professor of Medicine, Division of Hematology/Oncology at UT Health Science Center and the leader of the Breast Cancer

8

Program at the Cancer Therapy & Research Center assumed the role of Co-Director of the Symposium.

The UT Health Science Center San Antonio School of Medicine, through the Office of Continuing Medical Education, continues to be the provider of CME sponsorship for this premier breast cancer symposium.

All administrative functions are the responsibility of the Symposia Director and occur in the Symposium operations office, which is located at Cancer Therapy & Research Center, 7979 Wurzbach, San Antonio, Texas 78229. All proceeds from registration and abstract fees, industry educational grants, and exhibit fees, are used for Symposium development and operations, and for support of its staff which consists of the Symposia Director, the Senior Meeting Planner, the Meeting Planner and the Administrative Assistant.

Meeting Goals/Purpose

This Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.

Target Audience

This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as other appropriate health care professionals. We anticipate 7,500 attendees from more than 90 countries.


9

10

SABCSTM Committee

Executive Committee

Program Planning Committee

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TNLisa A. Carey, University of North Carolina, Chapel Hill, NCGary C. Chamness, Baylor College of Medicine, Houston, TX (ex-officio)Margaret Foti, American Association for Cancer Research, Philadelphia, PAIsmail Jatoi, UT Health Science Center, San Antonio, TXVirginia G. Kaklamani, UT Health Science Center, San Antonio, TXKate Lathrop, UT Health Science Center, San Antonio, TX (ex-officio)Yi Li, Baylor College of Medicine, Houston, TXPatricia J. McCarroll, UT Health Science Center, San Antonio, TX (ex-officio)C. Kent Osborne, Baylor College of Medicine, Houston, TXMothaffar Rimawi, Baylor College of Medicine, Houston, TXIan M. Thompson, Jr., UT Health Science Center, San Antonio, TXRich Markow, UT Health Science Center, San Antonio, TX (ex-officio)

Fabrice André, Institut Gustav Roussy, Villejuif, FRANCECarlos L. Arteaga, AACR (Co-Chair), Vanderbilt-Ingram Cancer Ctr, Vanderbilt University, Nashville, TNMelissa L. Bondy, Baylor College of Medicine, Houston, TXMyles A. Brown, Dana-Farber Cancer Institute, Boston, MALisa A. Carey, University of North Carolina, Chapel Hill, NCGary C. Chamness, Baylor College of Medicine, Houston, TX (ex-officio)Jenny C. Chang, Houston Methodist Cancer Center, Houston, TXMargaret Foti, American Association for Cancer Research, Philadelphia, PA (ex-officio)Matthew P. Goetz, Mayo Clinic, Rochester, MNIsmail Jatoi, UT Health Science Center, San Antonio, TXVirginia G. Kaklamani (Co-Chair), UT Health Science Center, San Antonio, TXSeema A. Khan, Northwestern Medical Group, Chicago, IL


11

Kate Lathrop, UT Health Science Center, San Antonio, TX (ex-officio)Rong Li, UT Health Science Center, San Antonio, TXYi Li, Baylor College of Medicine, Houston, TXJulie Nangia, Baylor College of Medicine, Houston, TXRuth M. O’Regan, University of Wisconsin, Madison, WIC. Kent Osborne (Co-Chair), Baylor College of Medicine, Houston, TXCharles M. Perou, University of North Carolina, Chapel Hill, NCSusan W. Rafte, Pink Ribbons Project, Houston, TXMothaffar Rimawi, Baylor College of Medicine, Houston, TXJeffrey Rosen, Baylor College of Medicine, Houston, TXHope S. Rugo, University of California, San Francisco, CARachel Schiff, Baylor College of Medicine, Houston, TXRobert Setlik, Brooke Army Medical Center, Fort Sam Houston, TXKalliopi P. Siziopikou, Northwestern University Feinberg School of Medicine, Chicago, ILSandi Stanford, Alamo Breast Cancer Foundation, San Antonio, TXEric P. Winer, Dana-Farber Cancer Institute, Boston, MAXiang Zhang, Baylor College of Medicine, Houston, TX

12

Best of SABCSTM Local Committee

Executive Committee

Dr Abdul Hamid Abdul Rahman Al SubhiGeneral Director of Madinah Rigion, Health Affair General Director

Mr. Abdulaziz AlTurkiChairman, Saudi Cancer Foundation



13

Executive Committee

Dr. Majid Al JahelChairman of Oncology Department King Fahad General HospitalConsultant Medical OncologistMadina, Saudi Arabia

Dr. Ahmed Ali SaadeddinProfessor, King Saud Bin Abdulaziz University for Health Sciences Consultant Adult Medical Oncology Clinical Tutor and Education Supervisor, Department of Oncology King Abdulaziz Medical City for National Guard Health AffairsRiyadh, Saudi Arabia

Dr. Mohamed Adel Elsayes Conference CoordinatorMedical Director, Saudi Cancer FoundationAl Khobar, Saudi Arabia

14




Dr. Jamal Eddin ZekriConsultant Oncologist at King Faisal Specialist Hospital & Research CentreJeddah, Saudi Arabia

Dr. Heba ElzawahryProfessor of Medical Oncology Head of Medical Oncology DepartmentCairo University


15


Dr. Shaheenah Dawood

Dr. Hulayel AlharbiConsultant, Adult Medical Oncology King Fahad Specialist HospitalDammam, Saudi Arabia

Dr. Khalid AlsalehCIP Head of the Hematology and Oncology division Assistant professor Department of medicine, College of Medicine King Saud University,Riyadh, Saudi Arabia

16


Prof. Hesham El GhazalyProfessor of clinical oncology,Head of Medical Air Shams Research Institute (MASRI) President of BGICSChief of Oncology departments,General Organization of Teaching Hospitals and Institutes (GOTHI)

Dr. Medhat FarisConsultant Medical OncologistKing Fahad Specialist Hospital Dammam, Saudi Arabia

Dr. Ahmed Abdulfatah RefaeConsultant Medical Oncology

Dr. Samir ShehataConsultant Medical Oncologist Chairman of The Oncology Department, Assiut University, Egypt


17


Dr. Salah FayazConsultant Radiation Oncologist Head of Breast Cancer Unit, Radiation Oncology Department KCCC

Dr. Hamdy Abdel AzimPresident, Cairo Oncology CenterChairman & Professor of Clinical OncologyCairo UniversityEgypt

Dr. Wael ElmeloukClinical oncologist Specialized Medical Center Riyadh

Dr. Abdulaziz A. AlsaifProfessor of surgeryConsultant Breast & Endocrine surgery Program Director, breast & endocrine fellowship programRiyadh, Saudi Arabia

18


Dr. Ahlam Ahmad DohalChairman, Radiation Oncology DepartmentKing Fahad Specialist HospitalDammam, Saudi Arabia

Dr. Ihab Mohamed AnwarConsultant Medical OncologistKing Faisal Specialist HospitalRiyadh, Saudi Arabia

Dr. Mahmoud Al MasriChairman, Department of SurgeryConsultant, Surgical OncologistFull Member, Department of Surgery

Dr. Ahmed Ali SaadeddinProfessor, King Saud Bin Abdulaziz University for Health Sciences, Consultant Adult Medical Oncology Clinical Tutor and Education Supervisor, Department of Oncology King Abdulaziz Medical City for National Guard Health AffairsRiyadh, Saudi Arabia


19


Dr. Osama Malik

Dr. Khalid AlHajri

Dr. Enas Elkhouly

Dr. Mohammed RahalConsultant Medical Oncologist Department of Adult Medical OncologyKing Fahad Specialist HospitalDammam, Saudi Arabia

20


Dr. Emad HamadaProfessor Of Clinical Oncology at Kasr El Ainy Center Of Clinical Oncology And Nuclear Medicine (NEMROCK), Faculty Of Medicine, Cairo University

Dr. Hassan Jaffarmedical consultant in Tawam hospitalUAE

Dr. Shouki BazarbashiAlfaisal University HeadKing Faisal Specialist Hospital & Research CenterSaudi Arabia

Prof. Jean – marc NabholtzProfessor of medicineConsultant medical oncologistKing Saud Medical CityRiyadh, Saudi Arabia


21


Dr. Dahish AjarimConsultant Medical OncologistKing Faisal Specialist Hospital and Research Centre | KFSHRC

Dr. Taher AL TweigeriConsultant Medical Oncology, King Faisal Hospital and Research Center, Riyadh, Kingdom of Saudi Arabia

Dr. Ahmed S. Al Shehri Consultant Medical OncologistAssistant Professor- KSAU-HSSection Head Medical OncologyJeddah, Saudi Arabia

Dr. Fahad IbnshamsahConsultant, Adult Medical Oncology Chairman, Adult Medical Oncology Oncology Center, KFSH-Dammam Director, Outreach program, King Fahad Specialist Hospital Dammam, Saudi Arabia

22


Dr. Sami Ahmad KhatibSenior Clinical Oncologist – Amman,Jordan Senior Assistant Director General & Director of the Office of Cancer Planning and Public Outreach Programs at King Hussein Cancer Center (KHCC),Amman- Jordan

Dr. Esam MurshidPrince Sultan Military Medical CityDepartment of OncologyRiyadh


Dr. Meteb Al FoheidiBreast Medical OncologistNational Guard Health AffairsKing Saud Bin Abdulaziz University for Health SciencesJeddah, Saudi Arabia


23

Prof. Ezzeldin Ibrahim Senior ConsultantChief Medical officerDirector, Oncology CenterExecutive Director, Research CenterInternational Medical CenterJeddah, Saudi Arabia

Dr. Ahmed Al FarajConsultant Medical OncologistKing Fahad Specialist Hospital Dammam, Saudi Arabia


Prof. Sana Al SukhunConsultant in Medical Oncology/Hematology,President of Jordanian oncology society

Dr. Abdullah K. Altwairgi Consultant Medical Oncologist ,Program Director of Medical Oncology Fellowship ,Comprehensive Cancer Center,King Fahad Medical city Riyadh, Saudi Arabia

24


Dr. Adher Al-SayedConsultant Medical Oncologist | King Faisal Specialist Hospital and Research Center

Dr. Sharif Kullad

Dr. Banu ArunProfessor (Tenure), Department of Breast Medical OncologyDivision of Cancer MedicineThe University of Texas MD Anderson Cancer Center, Houston, TX

Dr. Ahmed AlwabariAssistant Professor in Medicine University of Arkansas for medical sciences Hematology/Oncology consultant Institute of Oncology at Johns Hopkins Aramco HealthcareDhahran, Kingdom of Saudi Arabia


25


Dr. Hikmat Abdel-RazeqDeputy Director, KHCCConsultant, Hematology and Medical OncologyChairman, Department of Internal MedicineFull Member, Department of Internal Medicine

Prof./ Dr. Alaa KandilProfessor of Clinical OncologyChairman, Department of Clinical OncologyAlexandria School of MedicineAlexandria, Egypt

Dr. Yasser Bahader Chairman, Department of RadiologyAssociate Professor and Consultant Radiation Oncology King Abdulaziz UniversityJeddah, Saudi Arabia

Dr. Abdullah Al SharmConsultant Medical OncologistChairman of The Oncology Department King Fahad Medical City,Riyadh, Saudi Arabia

26


Dr. Huda Al AbdulkareemConsultant Medical OncologyComprehensive Cancer CentreKing Fahad Medical CityRiyadh, Saudi Arabia

Dr. Falah AlkhatibMediclinic Middle East · Department of Radiation Oncology

Dr. Bilal Abusaida

Dr. Suzan Hassanan


27

28

Program Agenda

“The 12th Middle East Best of San Antonio Breast Cancer Symposium”26-27 January 2018

Le Meridien Hotel, Madinah

DAY 1,FRIDAY, 26 January 2018

TIME

09:00am - 09:10am

09:10am - 10:40am EARLY BREAST CANCER

09:10am - 09:25am

TOPICS

GS1-01. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials

Speaker : Dr. Shaheenah Dawood

09:25am - 09:40am GS3-01. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

09:40am - 09:55am GS3-04. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

Dr. Heba Elzawahry, Dr. Jamal Eddin Zekri, Dr. Nasr AllahloubiChairpersons :

Speakers: Dr. Khalid Alsaleh

Welcome and Opening RemarksSpeakers: Dr. Omalkhair Abulkhair, Dr. Maged Algahel

Speaker : Dr. Hulayel Alharbi


29

Program Agenda

“The 12th Middle East Best of San Antonio Breast Cancer Symposium”26-27 January 2018

Le Meridien Hotel, Madinah


TIME

09:00am - 09:10am

09:10am - 10:40am EARLY BREAST CANCER

09:10am - 09:25am

TOPICS

GS1-01. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials

Speaker : Dr. Shaheenah Dawood

09:25am - 09:40am GS3-01. A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of Anastrozole after initial 5 years of adjuvant endocrine therapy - results from 3,484 postmenopausal women in the ABCSG-16 trial

09:40am - 09:55am GS3-04. A randomized phase III study of adjuvant trastuzumab for a duration of 9 weeks versus 1 year, combined with adjuvant taxane-anthracycline chemotherapy, for early HER2-positive breast cancer (the SOLD study)

Dr. Heba Elzawahry, Dr. Jamal Eddin Zekri, Dr. Nasr AllahloubiChairpersons :

Speakers: Dr. Khalid Alsaleh

Welcome and Opening RemarksSpeakers: Dr. Omalkhair Abulkhair, Dr. Maged Algahel

Speaker : Dr. Hulayel Alharbi

TIME

09:55am - 10:10am

TOPICS

GS4-02. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials

10:10am - 10:25am GS4-01. Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

10:25am - 10:40am GS4-03. Randomized comparison of adjuvant tamoxifen (T) plus ovarian function suppression (OFS) versus tamoxifen in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Update of the SOFT trial

Speakers: Dr. Medhat Faris

Speakers: Dr. Ahmed Abdulfatah Refae

10:40am - 11:00am BREAK

Speakers: Prof. Hesham El Ghazaly


30

TIME TOPICS

SPEAKERS: Dr. Hamdy Abdel Azim

11:20am – 11:35am GS1-06. Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study

11:35am – 11:50am Case presentation

11:50am – 12:00pm Discussion

12:00pm - 01:30pm PRAYER AND LUNCH BREAK

01:30pm - 02:05pm SURGICAL UPDATEChairpersons : Dr. Abdulaziz A. Alsaif, Dr. Ihab Mohamed Anwar, Dr. Ahlam Ahmad Dohal

01:30pm - 01:50pm Individualizing management of the axillary nodes

SPEAKERS: Dr. Mahmoud Al Masri

01:50pm - 02:05pm GS5-01. Appropriate margins for breast conserving surgery in patients with early stage breast cancer: A meta-analysis

SPEAKERS: Dr. Osama Malik

11:00am - 12:00am

SPEAKERS: Dr. Hamdy Abdel Azim11:00am – 11:20am Introduction to bone health

UPDATE ON BONE HEALTH(SUPPORTED BY AMGEN)Chairpersons : Dr. Omalkhair Abulkhair, Dr. Salah Fayaz, Dr. Samir Shehata

SPEAKERS: Dr. Wael Elmelouk



31

TIME TOPICS

SPEAKERS: Dr. Hamdy Abdel Azim

11:20am – 11:35am GS1-06. Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study

11:35am – 11:50am Case presentation

11:50am – 12:00pm Discussion


01:30pm - 02:05pm SURGICAL UPDATEChairpersons : Dr. Abdulaziz A. Alsaif, Dr. Ihab Mohamed Anwar, Dr. Ahlam Ahmad Dohal

01:30pm - 01:50pm Individualizing management of the axillary nodes

SPEAKERS: Dr. Mahmoud Al Masri

01:50pm - 02:05pm GS5-01. Appropriate margins for breast conserving surgery in patients with early stage breast cancer: A meta-analysis

SPEAKERS: Dr. Osama Malik

11:00am - 12:00am

SPEAKERS: Dr. Hamdy Abdel Azim11:00am – 11:20am Introduction to bone health

UPDATE ON BONE HEALTH(SUPPORTED BY AMGEN)Chairpersons : Dr. Omalkhair Abulkhair, Dr. Salah Fayaz, Dr. Samir Shehata

SPEAKERS: Dr. Wael Elmelouk


TIME TOPICS

02:05pm - 02:35pm ABSTRACT PRESENTATIONFROM THE MIDDLE EAST

02:05pm - 02:20pm Abstract #1

Chairpersons : Dr. Ahmed Ali Saadeddin, Dr. Omalkhair Abulkhair, Dr. Heba Elzawahry, Dr. Khalid AlHajri

02:35pm - 04:00pm IMMUNO-ONCOLOGY PART 1(SUPPORTED BY BMS/MSD)Chairpersons : Dr. Adher Al-Sayed, Dr. Emad Hamada, Dr. Maher Aidarous

SPEAKERS: Dr. Suzan Hassanan

02:20pm - 02:35pm Abstract #2SPEAKERS: Dr. Enas Elkhouly

02:35pm - 03:00pm General introduction to immune therapy, current understanding

SPEAKERS: Prof. Jean – marc Nabholtz

03:00pm - 03:15pm Immuno-therapy updates in lung cancer

SPEAKERS: Dr. Hassan Jaffar

03:15am - 03:30am Immuno-therapy updates in bladder cancer

SPEAKERS: Dr. Mohammed Rahal

03:30pm - 03:45pm Immuno-therapy updates in kidney cancer

03:45pm - 04:00pm Immuno-therapy updates in colorectal cancer

04:00pm END OF DAY 1

SPEAKERS: Dr. Ahmed S. Al Shehri

SPEAKERS: Dr. Fahad Ibnshamsah


32

DAY 2,SATURDAY, 27 January 2018

TIME TOPICS

07:00am - 09:00am OPENING CEREMONY & GALA DINNER

09:00am - 12:00pm ADVANCE AND METASTATIC BREAST CANCER (SUPPORTED BY NOVARTIS & PFIZER)A- Hormonal positive breast cancerChairpersons : Dr. Ahmed Ali Saadeddin, Dr. Dahish Ajarim, Dr. Sami Ahmad Khatib

09:00am - 09:30am Metastatic breast cancer: Endocrine therapy landscape reshapedSPEAKERS: Dr. Taher AL Tweigeri

09:30am - 09:40am GS2-05. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

SPEAKERS: Dr. Majid Al Jahel

09:40am - 09:50am GS2-07. MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

SPEAKERS: Dr. Meteb Al Foheidi

09:50am - 10:05am Efficacy and Safety of Palbociclib Plus Letrozole as First-Line Therapy in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Findings by Geographic Region From PALOMA-2

SPEAKERS: Dr. Esam Murshid


33


TIME TOPICS

07:00am - 09:00am OPENING CEREMONY & GALA DINNER

09:00am - 12:00pm ADVANCE AND METASTATIC BREAST CANCER (SUPPORTED BY NOVARTIS & PFIZER)A- Hormonal positive breast cancerChairpersons : Dr. Ahmed Ali Saadeddin, Dr. Dahish Ajarim, Dr. Sami Ahmad Khatib

09:00am - 09:30am Metastatic breast cancer: Endocrine therapy landscape reshapedSPEAKERS: Dr. Taher AL Tweigeri

09:30am - 09:40am GS2-05. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

SPEAKERS: Dr. Majid Al Jahel

09:40am - 09:50am GS2-07. MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer

SPEAKERS: Dr. Meteb Al Foheidi

09:50am - 10:05am Efficacy and Safety of Palbociclib Plus Letrozole as First-Line Therapy in Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Findings by Geographic Region From PALOMA-2

SPEAKERS: Dr. Esam Murshid

TIME TOPICS

10:05am - 10:15am Palbociclib exposure-response analyses in the treatment of hormone-receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC)SPEAKERS: Prof. Ezzeldin Ibrahim

10:50am – 11:00am GS3-06. Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (IX) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)SPEAKERS: Dr. Ahmed Al Faraj

11:00am - 11:15am GS3-08. Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

SPEAKERS: Dr. Lobna Sedky

10:15am - 10:25am GS6-02. The benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studiesSPEAKERS: Dr. Abdullah K. Altwairgi

10:25am - 10:35am Discussion

10:35am - 10:50am BREAK


34

TIME TOPICS

11:15am - 12:00am ADVANCE AND METASTATIC BREAST CANCER B-HER2 Over Expression Breast Cancer Cases From ClinicChairpersons : Dr. Omalkhair Abulkhair, Dr. Banu Arun, Dr. Majid Al Jahel

01:00pm - 02:00pm UPDATE IN PARP INHIBITOR(SUPPORTED BY ASTRA ZENECA)Chairpersons : Dr. Taher AL Tweigeri, Dr. Adher Al-Sayed, Dr. Sharif Kullad

11:15am - 11:30am First line metastatic HER2 over expressed breast cancerSPEAKERS: Dr. Meteb Al Foheidi

11:30am - 11:45am Second line metastatic HER2 over expressed breast cancerSPEAKERS: Dr. Ahmed Ali Saadeddin

01:00pm - 01:15pm IntroductionSPEAKERS: Dr. Banu Arun

01:15pm - 01:30pm GS4-06. Cancer risks and response to targeted therapy associated with BRCA2variants of uncertain significance

SPEAKERS: Dr. Banu Arun

01:30pm - 01:45pm GS6-07. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutationSPEAKERS: Dr. Banu Arun

11:45am - 12:00pm Discussion , Q & A


01:45pm - 02:00pm Discussion



35

TIME TOPICS

11:15am - 12:00am ADVANCE AND METASTATIC BREAST CANCER B-HER2 Over Expression Breast Cancer Cases From ClinicChairpersons : Dr. Omalkhair Abulkhair, Dr. Banu Arun, Dr. Majid Al Jahel

01:00pm - 02:00pm UPDATE IN PARP INHIBITOR(SUPPORTED BY ASTRA ZENECA)Chairpersons : Dr. Taher AL Tweigeri, Dr. Adher Al-Sayed, Dr. Sharif Kullad

11:15am - 11:30am First line metastatic HER2 over expressed breast cancerSPEAKERS: Dr. Meteb Al Foheidi

11:30am - 11:45am Second line metastatic HER2 over expressed breast cancerSPEAKERS: Dr. Ahmed Ali Saadeddin

01:00pm - 01:15pm IntroductionSPEAKERS: Dr. Banu Arun

01:15pm - 01:30pm GS4-06. Cancer risks and response to targeted therapy associated with BRCA2variants of uncertain significance

SPEAKERS: Dr. Banu Arun

01:30pm - 01:45pm GS6-07. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutationSPEAKERS: Dr. Banu Arun

11:45am - 12:00pm Discussion , Q & A


01:45pm - 02:00pm Discussion



TIME TOPICS

02:00pm - 02:15pm Immuno-therapy and breast cancer updates, current understanding and future directionsSPEAKERS: Dr. Hikmat Abdel-Razeq

02:15pm - 02:30pm GS2-06. Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/KEYNOTE-014) studySPEAKERS: Prof./ Dr. Alaa Kandil

02:30pm - 02:45pm Updates in immuno-therapy in head and neck cancerSPEAKERS: Dr. Falah Alkhatib

02:45pm - 03:00pm Interaction between immuno-therapy and radiotherapySPEAKERS: Dr. Yasser Bahader

03:00pm - 03:15pm Abstract # 3SPEAKERS: Dr. Suzan Hassanan

03:15pm - 03:30pm Abstract # 4SPEAKERS: Dr. Bilal Abusaida

03:30pm - 03:45pm Announcement of Abstract winners and Raffle draw

03:45pm - 04:00pm CLOSING REMARKS

02:00pm - 03:00pm UPDATE IN IMMUNE-ONCOLOGY PART 2 (SUPPORTED BY MSD/BMS)Chairpersons : Dr. Abdullah Al Sharm, Dr. Esam Murshid, Dr. Ahmed Alwabari

03:00pm - 03:40pm ABSTRACT FROM THE MIDDLE EASTChairpersons : Dr. Ahmed Ali Saadeddin, Dr. Omalkhair Abulkhair, Prof. Jean – marc Nabholtz

36

Notes


37

Notes

38

Notes


39

Notes

40

Notes

An Initiative of

S a u d i C a n c e r F o u n d a t i o n

CME15 accredited

Le-Meredian MadinahAl Madinah - Saudi Arabia

26-27 Jan, 2018

Le-Meredian Madinah Al Madinah - Saudi Arabia 26-27 Jan,...

Documents

Transcript of Le-Meredian Madinah Al Madinah - Saudi Arabia 26-27 Jan,...